GW Henssler & Associates Ltd. Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GW Henssler & Associates Ltd. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,817 shares of the biopharmaceutical company’s stock after selling 251 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Regeneron Pharmaceuticals were worth $12,692,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $49,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $672.98 on Monday. The stock has a 50 day moving average of $720.81 and a two-hundred day moving average of $922.87. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The firm has a market cap of $73.95 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Barclays decreased their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.